­

About admin

This author has not yet filled in any details.
So far admin has created 77 blog entries.

Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement

BATON ROUGE, LA--(July 13, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged [...]

OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico

BATON ROUGE, LA--(June 28, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged [...]

Enrollment to Begin in OncBioMune’s Trial of ProscaVax for Prostate Cancer in Mexico

BATON ROUGE, LA—(June 27, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a revenue-stage biopharmaceutical company engaged [...]

OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico

BATON ROUGE, LA—(June 21, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged [...]

OncBioMune Awarded Patent for ProscaVax in Japan

BATON ROUGE, LA--(June 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged [...]

OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico

MEXICO CITY, MEXICO--(June 19, 2017) - OncBioMune México, S.A. De C.V., (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical [...]

OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)

BATON ROUGE, LA--(June 15, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong

BATON ROUGE, LA--(June 07, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged [...]

OncBioMune’s Andfrt(R) Shown in Clinical Trial to Improve Sperm Count and Mobility

BATON ROUGE, LA--(June 06, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged [...]

Protocol Submitted to FDA for Phase 2 Clinical Trial of ProscaVax as Immunotherapy for Early-Stage Prostate Cancer

BATON ROUGE, LA—(June 01, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]